Malignant hyperthermia (MH) is estimated to occur in roughly 1 in 5,000 to 1 in 100,000 general anesthesia cases, making it one of the rarer anesthetic emergencies. That wide range reflects the difficulty of pinpointing exact numbers: mild cases can go unrecognized, and genetic susceptibility is far more common than actual clinical events. Despite its rarity, MH is taken seriously because untreated episodes were fatal about 70 to 80% of the time before an effective treatment became available in the late 1970s.
What the Incidence Numbers Mean
The 1-in-5,000 to 1-in-100,000 range describes how often a full MH episode is triggered during surgery under general anesthesia. The lower end of that range likely reflects settings that capture milder or “abortive” episodes, while the higher end counts only the classic, unmistakable crises. Either way, if you’re going under general anesthesia for a routine procedure, the absolute risk is small.
But incidence and genetic susceptibility are two different things. Among confirmed MH-susceptible families who have been tested, about 86% carry a mutation in the RYR1 gene, which controls how calcium is released inside muscle cells. Another small percentage carry mutations in a related gene called CACNA1S. Some people who test positive on muscle biopsy carry no identified mutation at all, suggesting other genes may be involved. The key point is that many more people carry a predisposing mutation than will ever have a clinical episode, because a crisis only happens when a susceptible person is exposed to specific trigger drugs.
Who Is Most at Risk
MH is not evenly distributed across age and sex. Males are roughly 2.5 to 4.5 times more likely to have a documented episode than females, and nearly half of all cases occur in people 19 or younger. The median age at presentation is about 22, with a mean age of around 18. Children and young adults face higher rates partly because they’re more likely to receive the types of anesthesia that trigger MH and partly because many susceptible individuals simply haven’t been exposed to those agents yet.
Geography plays a role too. Certain families with MH susceptibility cluster in specific regions. In the United States, Wisconsin and the upper Midwest have notable concentrations of MH-susceptible families. Similar clusters exist in parts of Europe. Because MH is inherited in an autosomal dominant pattern, meaning you only need one copy of the mutation from one parent, a single affected family can produce many susceptible relatives across generations.
What Triggers an Episode
MH only occurs when a genetically susceptible person receives certain anesthetic agents. The triggers are volatile inhaled anesthetics (halothane, sevoflurane, desflurane, isoflurane, and enflurane) and a specific muscle relaxant called succinylcholine. These can act alone or in combination. No other commonly used medications are known to trigger MH.
This is important because safe alternatives exist. Regional anesthesia (nerve blocks, spinals, epidurals), local anesthesia, and total intravenous general anesthesia all avoid the triggering agents entirely. If you know you’re susceptible, or if MH runs in your family, these approaches let you have surgery safely. The condition only becomes dangerous when susceptibility is unknown and a triggering agent is used.
How MH Is Diagnosed
Diagnosing susceptibility before a crisis happens is tricky. The gold-standard test is a muscle biopsy procedure where a small piece of thigh muscle is exposed to caffeine and halothane in a lab to see if it contracts abnormally. The North American version of this test has a sensitivity of about 97%, meaning it catches nearly all susceptible individuals. Its specificity is lower, around 78%, so it occasionally labels someone as susceptible when they aren’t. Only a handful of specialized centers worldwide perform this test, which limits its availability.
Genetic testing for RYR1 mutations is increasingly used as a less invasive option. If a known disease-causing mutation is found, that confirms susceptibility without a muscle biopsy. The limitation is that not all causative mutations have been identified yet. A negative genetic test doesn’t fully rule out susceptibility, which is why the muscle biopsy remains relevant for inconclusive cases.
Survival Rates Then and Now
Before the introduction of dantrolene in the late 1970s, MH had a case-fatality rate of roughly 70 to 80%. Today that number is below 5%. Dantrolene works by blocking the runaway calcium release in muscle cells that drives the crisis, essentially shutting down the chain reaction that causes dangerously high body temperature, muscle rigidity, and metabolic collapse.
Speed matters enormously. When an MH episode is recognized quickly and dantrolene is administered early, most patients recover fully. Modern anesthesia monitors that track exhaled carbon dioxide levels and body temperature make it easier to catch the earliest signs of a reaction, often before a full-blown crisis develops. Operating rooms and surgery centers are required to stock dantrolene for exactly this reason.
What This Means for You
If you have no family history of MH and no personal history of anesthetic complications, your risk of experiencing an episode is extremely low. The condition is rare enough that routine pre-surgical screening of the general population isn’t practical or recommended.
The picture changes if a blood relative has had a confirmed or suspected MH episode, or if you’ve had an unexplained reaction during anesthesia yourself. In those situations, testing is worthwhile, and informing your anesthesiologist before any procedure is critical. Wearing a medical alert bracelet or registering with a national MH registry ensures the information follows you to any future surgery. With proper precautions, people who carry MH susceptibility undergo anesthesia safely throughout their lives.